A Milestone in Women's Health; First Pill for Postpartum Depression Approved in the U.S.

The U.S. Food and Drug Administration has approved the first oral pill for postpartum depression. This action marks a milestone in the diagnosis and treatment of this debilitating condition that affects about half a million women in the U.S. each year. If left untreated, this disorder can impact the lives of these mothers for months or even years. The FDA announced that the pill 'Zuranolone' has been approved for once-daily use for two weeks. Postpartum depression is a serious condition in which mothers experience feelings of sadness, guilt, and worthlessness, and in severe cases, it can be accompanied by thoughts of self-harm or harm to their child. Tiffany Farquharson, director of psychiatry at the FDA's Center for Drug Evaluation and Research, states that postpartum depression can disrupt the bond between mother and baby and can have consequences for the child's physical and emotional development. She emphasizes that access to an oral medication will be a beneficial option for many women suffering from this condition. Women often seek counseling to cope with postpartum depression, and previously, the only FDA-approved treatment was an injection called 'Zulresso,' which could only be administered in certain healthcare facilities. The new pill can be taken at home and acts quickly. The FDA warned that the side effects of this medication may include drowsiness, dizziness, fatigue, diarrhea, and urinary tract infections. The agency also cautioned that patients should not drive for at least 12 hours after taking the pill. 'Zuranolone' is a neurosteroid closely related to allopregnanolone, a substance that naturally exists in the body and significantly increases during pregnancy, only to decrease sharply after childbirth. This process may lead to postpartum depression in some women. Researchers have warned that postpartum depression may have serious causes, including genetics, social and economic factors, and trauma from domestic violence, and thus, this pill cannot work miracles. Experts say that longer maternity leave, more flexible work schedules, social support for women, and the establishment of childcare systems can help address the issue of postpartum depression more broadly and fundamentally. In Iran, postpartum depression is also common, but reported statistics vary from 25% to 45%, and there is no effective system for identifying cases of this illness. The Iranian forensic organization also lacks options in its suicide data collection forms regarding women's pregnancy at the time of suicide, childbirth within six weeks prior, and the time interval between childbirth and suicide, indicating that no appropriate mechanism has been established in this regard. Postpartum care in Iran typically relies on traditional methods, including emotional support and assistance from relatives, which, while not ineffective, do not directly address and treat this illness. Health experts emphasize that a proper screening system needs to be established in Iran, with a greater focus on raising awareness among healthcare providers and pregnant women. A representative of the Iranian midwifery community in the Supreme Medical Council reported the suicide of sixteen pregnant women in 2021 and noted the unemployment of many midwives and the closure of midwifery centers that play a crucial role in caring for pregnant women. The World Health Organization's statistics show that globally, about 10% of pregnant women and 13% of women who have recently given birth experience some form of mental disorder, primarily depression. In developing countries, this rate is higher, exceeding 15% during pregnancy and about 20% after childbirth. The WHO states that globally, more than 3 in 10 women and newborns do not receive postpartum care in the days following birth, a period with the highest maternal and neonatal mortality rates. If necessary care is provided in a timely manner, many women will be able to overcome postpartum depression and debilitating mental disorders. This report utilized sources such as the Washington Post, Associated Press, the World Health Organization, and research from Mazandaran University of Medical Sciences and Kermanshah Medical School.